Navocaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.
KIT-2014 is under development for the treatment of cystic fibrosis, chronic obstructive pulmonary disease and asthma. The therapeutic candidate acts by targeting phosphoinositide 3-kinase gamma. It is ...
An international study has identified two types of these so-called dysbioses in cystic fibrosis. They display ... Landmark Study Involving Babies in Ireland Supports Use of Cystic Fibrosis Drug in ...
LCI proves valuable in monitoring ETI therapy effectiveness for cystic fibrosis patients with minimal FEV1 changes, detecting ...
DelveInsight, a leader in healthcare competitive intelligence and consulting company, published a success study on Digital ...
GlobalData on MSN8d
Vertex secures two FDA wins for cystic fibrosis, both with boxed warningsVertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.
As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and ...
Whether you are dealing with severe consequences of cystic fibrosis or want to get ahead the symptoms, these tips will help.
Zacks.com on MSN8d
Vertex Secures FDA Approval for New Cystic Fibrosis Drug AlyftrekThe FDA's nod is based on late-stage data, which show that treatment with VRTX's Alyftrek enhances patient benefit compared ...
The Boomer and Gunnar Esiason Story," detailing a remarkable father-son journey of perseverance and resilience.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback